Navigation Links
Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
Date:5/6/2009

Clinical results and advantage over linezolid in resistance acquisition by Staph aureus among data to be presented at infectious disease meeting

SAN DIEGO, Calif., May 6 /PRNewswire/ -- Trius Therapeutics, Inc., a biopharmaceutical company developing best-in-class drugs for the treatment of serious bacterial infections, announced today that the results of multiple studies from its lead program, torezolid (TR-701), will be presented in an oral session and six poster presentations at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting in Helsinki, Finland May 16-19. Torezolid is a novel antibiotic that recently completed Phase 2 clinical development with potent activity against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).

The presentations are as follows:

Saturday, May 16th

Oral Presentation - Lecture Hall 3a (14:54 - 15:06)

  • O28: In vivo pharmacodynamics of TR-701, a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains; A. Louie, C. Fregeau, W. Liu, H. Conde, R. Kulawy, G. Drusano

Sunday, May 17th

Poster Presentations - New antimicrobials against Gram-positives (13:30 - 14:30)

  • P 1091: Effects of food on the pharmacokinetics of TR-701, a novel oxazolidinone prodrug antibiotic, in healthy adult subjects; KA. Munoz, P. Bien, P. Prokocimer, M. Berry, C. R. Bethune
  • P 1092: TR-700, a novel methyltetrazolyl-oxazolidinone, accumulates extensively within human macrophages cells and shows activity towards intraphagocytic linezolid-sensitive and linezolid-resistant S. aureus; S. Lemaire, K. Kosowska-Shick, P. Appelbaum, F. Van Bambeke, P. Tulkens
  • P 1090: The safety of single ascending oral doses of TR-701, a novel oxazolidinone prodrug antibiotic; P. Bien, P. Prokocimer, KA. Munoz, J. Bohn
  • P 1089: The safety of multiple ascending oral doses of TR-701, a novel oxazolidinone prodrug antibiotic; P. Bien, P. Prokocimer, KA. Munoz, J. Bohn
  • P 1103: Characterization of resistance following serial passage of Staphylococcus aureus in the presence of the novel oxazolidinone TR-700 and linezolid; J. Locke, K. Shaw
  • P 1104: Characterization of the novel oxazolidinone TR-700 and linezolid spontaneous mutation frequencies and resistance mechanisms in Staphylococcus aureus; J. Locke, K. Shaw

Copies of these posters will be available on the Trius Web site following the ECCMID meeting: http://www.triusrx.com/posters.php.

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company's lead drug candidate, torezolid, is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant Gram-positive bacterial pathogens including those resistant to Zyvox(R), the only marketed antibacterial drug of the oxazolidinone class. Trius has recently completed Phase 2 testing of torezolid in a U.S. based multi-center trial. Trius' pipeline includes two preclinical programs with lead candidates being developed to treat serious infections caused by Gram-negative bacterial pathogens. For more information, visit www.triusrx.com.


'/>"/>
SOURCE Trius Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
2. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
3. Trius Doses First Patient in Antibacterial Phase 2 Trial
4. PacificGMP Completes GMP Product Fill for Trius Therapeutics
5. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
6. Hyperion Therapeutics Receives Orphan Drug Designation for HPN-100 for the Treatment of Urea Cycle Disorders
7. Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
8. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
9. Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders
10. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
11. Vantia Therapeutics Pipeline Continues to Mature
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... FDA 510(k) clearance covers ... for urological and surgical applications Mauna ... Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) platform, ... US with the 12 th 510(k) clearance ... This new FDA clearance covers Confocal Miniprobes indicated ...
(Date:5/25/2016)... , May 25, 2016  Zymo Research ... for their new reference materials that help researchers ... sample collection to analyses. The rapid growth of ... for researchers to have standard methods to improve ... generated. Biases inherently exist at every step of ...
(Date:5/25/2016)... 2016  Granger Diagnostics today announced immediate availability of ... infections. This test ensures discovery of ALL bacteria, ... test requires only a simple swab of the wound ... G. Bostwick , MD, Chief Medical Officer, described ... "We are excited to make available, for the ...
Breaking Medicine Technology:
(Date:5/26/2016)... LINCOLN, R.I. (PRWEB) , ... May 26, 2016 , ... ... season. That’s why Amica Insurance is sharing tips to make sure your ... an estimate from the National Safety Council, there may be 439 deaths and an ...
(Date:5/26/2016)... ... May 26, 2016 , ... The Lung Institute has partnered with ... class starting June 6 at their clinic in downtown Tampa. The class is complimentary ... Lung Institute has created a free downloadable 4 Week Smoking Cessation Guide ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... of Mehling Orthopedics and chief medical officer of Blue Horizon International (BHI), Brian ... Regeneration. The conference was held during May 5-6, 2016 in Chicago, IL, USA. ...
(Date:5/26/2016)... ... May 26, 2016 , ... Power Systems, a leading developer ... Instructor Certification Course in Stoughton, Massachusetts. The course was led by Power Systems’ ... 8 hour interactive course to qualify participants as certified PowerWave trainers. , ...
(Date:5/26/2016)... ... May 26, 2016 , ... On May 23rd during the National ... Science® and international water advocate, was honored by Ashram, Inc. as the world’s foremost ... who knelt on the banks of the Nile to fill their red clay pots ...
Breaking Medicine News(10 mins):